Merck checkpoint inhibitor Keytruda has been hit a sitback during a Phase 3 trial, having failed to extend survival in previously treated patients with advanced head and neck cancer compared to the standard treatment.
The company announced the news as well as the fact that the U.S. Food and Drug Administration will not be removing Keytruda's conditional approval, which the FDA gave fast-track approval for head and neck cancer last year.
Read the Merck release